Table 1.
Definitions of nine groups at risk of multidrug-resistant TB in line with Indonesian guidelines for programmatic management of drug-resistant TB.
Fig 1.
Diagnosis and treatment of individuals at risk of multidrug-resistant pulmonary TB at three provincial hospitals in Java, Indonesia.
The flowchart shows the number of tested, detected and treated individuals in two cohort years. From March 2011 to Feb 2012 (Year 1), individuals were tested with conventional culture and drug-susceptibility testing. From March 2012 to February 2013 (Year 2), individuals were tested with culture and drug-susceptibility testing or Xpert MTB/RIF. Abbreviations: TB, tuberculosis; DST, drug-susceptibility testing; RIF, rifampicin; MDR-TB, multidrug-resistant TB; N, number.
Table 2.
Characteristics of individuals at risk of multidrug-resistant pulmonary TB registered from March 2011 to February 2012 (Year 1) and March 2012 to February 2013 (Year 2) at three provincial hospitals in Java, Indonesia.
Fig 2.
Time to diagnosis and treatment of rifampicin-resistant TB patients in three provincial hospitals in Java, Indonesia.
These figures show Kaplan Meier time-to-event graphs of health system delays (a), diagnostic delays (b) and treatment delays (c) for rifampicin resistance TB patients detected with culture drug-susceptibility testing from March 2011 to February 2012 and Xpert MTB/RIF from March 2012 to February 2013. Abbreviations: TB, tuberculosis; DST, drug-susceptibility testing; RIF, rifampicin.
Table 3.
Culture and drug-susceptibility testing results following Xpert MTB/RIF testing within the same individuals at risk of multidrug-resistant TB in three provincial hospitals in Java, Indonesia.
Table 4.
Follow-on culture results among individuals from various risk groups that tested Xpert MTB/RIF TB positive in three provincial hospitals in Java, Indonesia.